» Articles » PMID: 35965596

Emerging Evidence for Intrathecal Management of Neuropathic Pain Following Spinal Cord Injury

Overview
Date 2022 Aug 15
PMID 35965596
Authors
Affiliations
Soon will be listed here.
Abstract

A high prevalence of patients with spinal cord injury (SCI) suffer from chronic neuropathic pain. Unfortunately, the precise pathophysiological mechanisms underlying this phenomenon have yet to be clearly elucidated and targeted treatments are largely lacking. As an unfortunate consequence, neuropathic pain in the population with SCI is refractory to standard of care treatments and represents a significant contributor to morbidity and suffering. In recent years, advances from SCI-specific animal studies and translational models have furthered our understanding of the neuronal excitability, glial dysregulation, and chronic inflammation processes that facilitate neuropathic pain. These developments have served advantageously to facilitate exploration into the use of neuromodulation as a treatment modality. The use of intrathecal drug delivery (IDD), with novel pharmacotherapies, to treat chronic neuropathic pain has gained particular attention in both pre-clinical and clinical contexts. In this evidence-based narrative review, we provide a comprehensive exploration into the emerging evidence for the pathogenesis of neuropathic pain following SCI, the evidence basis for IDD as a therapeutic strategy, and novel pharmacologics across impactful animal and clinical studies.

Citing Articles

Comparative outcomes of microsurgical dorsal root entry zone lesioning (DREZotomy) for intractable neuropathic pain in spinal cord and cauda equina injuries.

Sitthinamsuwan B, Ounahachok T, Pumseenil S, Nunta-Aree S Neurosurg Rev. 2025; 48(1):17.

PMID: 39747752 PMC: 11695575. DOI: 10.1007/s10143-024-03136-y.


Neuropathic Pain Induced by Spinal Cord Injury from the Glia Perspective and Its Treatment.

Ye Y, Su X, Tang J, Zhu C Cell Mol Neurobiol. 2024; 44(1):81.

PMID: 39607514 PMC: 11604677. DOI: 10.1007/s10571-024-01517-x.


Concise review: Current understanding of extracellular vesicles to treat neuropathic pain.

Zhang K, Li P, Jia Y, Liu M, Jiang J Front Aging Neurosci. 2023; 15:1131536.

PMID: 36936505 PMC: 10020214. DOI: 10.3389/fnagi.2023.1131536.


Resveratrol suppresses neuroinflammation to alleviate mechanical allodynia by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of spinal cord injury.

Han J, Hua Z, Yang W, Wang S, Yan F, Wang J Front Mol Neurosci. 2023; 16:1116679.

PMID: 36873101 PMC: 9977815. DOI: 10.3389/fnmol.2023.1116679.

References
1.
Taves S, Berta T, Chen G, Ji R . Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast. 2013; 2013:753656. PMC: 3759269. DOI: 10.1155/2013/753656. View

2.
Hulsebosch C, Hains B, Crown E, Carlton S . Mechanisms of chronic central neuropathic pain after spinal cord injury. Brain Res Rev. 2009; 60(1):202-13. PMC: 2796975. DOI: 10.1016/j.brainresrev.2008.12.010. View

3.
Huang Q, Duan W, Sivanesan E, Liu S, Yang F, Chen Z . Spinal Cord Stimulation for Pain Treatment After Spinal Cord Injury. Neurosci Bull. 2018; 35(3):527-539. PMC: 6527651. DOI: 10.1007/s12264-018-0320-9. View

4.
Ruiz-Sauri A, Orduna-Valls J, Blasco-Serra A, Tornero-Tornero C, Cedeno D, Bejarano-Quisoboni D . Glia to neuron ratio in the posterior aspect of the human spinal cord at thoracic segments relevant to spinal cord stimulation. J Anat. 2019; 235(5):997-1006. PMC: 6794197. DOI: 10.1111/joa.13061. View

5.
Decosterd I, Woolf C . Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000; 87(2):149-158. DOI: 10.1016/S0304-3959(00)00276-1. View